Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 872 across all filing types
Latest filing 2025-12-18 Regulatory Filings
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Abivax fait son entree au sein de l'indice Nasdaq Biotechnology
Regulatory Filings Classification · 1% confidence The document is a press release announcing that Abivax has been included in the Nasdaq Biotechnology Index. It is a corporate announcement regarding company status and market visibility, which does not fit into specific categories like financial reports, M&A, or director dealings. As it is a general regulatory announcement provided via a news service (EQS Group), it falls under the fallback category of Regulatory Filings (RNS).
2025-12-18 French
Abivax annonce lacceptation de 22 abstracts sur obefazimod dans les MICI a lECCO 2026, dont une presentation orale sur des resultats precliniques antifibrotiques
Regulatory Filings Classification · 1% confidence The document is a press release from Abivax SA announcing the acceptance of 22 scientific abstracts for presentation at the upcoming ECCO 2026 congress. It details the nature of the research (obefazimod in IBD) and provides a schedule of the presentations. This is a standard corporate announcement regarding scientific communications and research dissemination, which falls under the 'Regulatory Filings' (RNS) category as it is a general corporate news announcement that does not fit into more specific categories like financial reports, board changes, or dividend notices.
2025-12-17 French
Abivax presente ses resultats financiers du troisieme trimestre 2025
Interim / Quarterly Report Classification · 1% confidence The document is a detailed financial report for the nine-month period ending September 30, 2025, for Abivax SA. It includes consolidated interim financial statements, detailed breakdowns of operating expenses (R&D, S&M, G&A), financial results, and a discussion of the company's financial position and liquidity. It is not a mere announcement (RPA) because it contains substantive financial data and tables. It fits the definition of an Interim/Quarterly Report (IR) as it covers a period shorter than a full fiscal year and provides comprehensive financial analysis. 9M 2025
2025-12-15 French
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 30.11.25.
Share Issue/Capital Change Classification · 1% confidence The document is a standard regulatory disclosure required by French law (Article L. 233-8 II of the Commercial Code and Article 223-16 of the AMF General Regulation) regarding the total number of shares and voting rights. This type of filing is a routine regulatory announcement concerning capital structure and voting rights, which does not fit into specific categories like 'Share Issue' (SHA) or 'Major Shareholding' (MRQ) as it is a periodic disclosure of the current state of the capital. Therefore, it falls under the 'Regulatory Filings' (RNS) category.
2025-12-12 French
ABIVAX: Nombre dactions composant le capital social et nombre total de droits de vote au 30.11.25.
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory disclosure from ABIVAX regarding the total number of shares and voting rights as of November 30, 2025, in accordance with Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation. This type of disclosure is a standard regulatory requirement for listed companies in France to inform the market about changes in capital structure and voting rights. It does not fit into specific categories like 'Share Issue' (SHA) as it is a periodic disclosure of existing totals, nor is it a 'Report Publication Announcement' (RPA) as it contains the actual data within the text. Therefore, it is best classified as a general Regulatory Filing (RNS).
2025-12-12 French
Franchissement de seuil et déclaration d'intention
Major Shareholding Notification Classification · 1% confidence The document is an official notification regarding a change in shareholding levels (crossing the 10% voting rights threshold) for the company ABIVAX, filed in accordance with Article L. 233-7 of the French Commercial Code. This type of regulatory disclosure regarding significant share ownership is classified as a Major Shareholding Notification.
2025-11-28 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.